Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
DOPTELET® (avatrombopag) approved May 21, 2018 and launched June 4, 2018
Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended December 31, 2018
sNDA accepted for review by FDA for DOPTELET for the treatment of
chronic immune thrombocytopenia (ITP) with a PDUFA goal date of June 30, 2019
Appointed Dr. David Zaccardelli as President and Chief Executive Officer and Jason Hoitt as Chief Commercial Officer
Conference call scheduled for 9:00 a.m. ET today
DURHAM, NC, March 5, 2019 - Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today reported its operating and financial results for the fourth quarter and full year ended December 31, 2018.
“Following the management changes announced in December 2018, we worked expeditiously to implement changes to our commercialization strategy for DOPTELET. We are encouraged with the initial feedback and results from these efforts and remain confident in the significant commercial opportunity for DOPTELET,” said Dr. David Zaccardelli, President and Chief Executive Officer of Dova. “In addition, we are pleased by the FDA acceptance of DOPTELET’s supplemental New Drug Application (sNDA) for review in the treatment of chronic ITP which would provide a new treatment option for patients with ITP as well as a long-term growth opportunity for DOPTELET. Finally, we remain well-positioned financially, with over $100 million in cash and equivalents as of December 31, 2018 to fund our operations.”
DOPTELET Launch Highlights
The US sales team was restructured on January 4, 2019, now comprised of 44 sales representatives and 5 regional directors. This team is accountable for driving DOPTELET sales in hepatology, hematology, and interventional radiology, while Dova’s co-promotion partner, Salix, has responsibility for GI, colorectal surgeon and proctology practices.
New DOPTELET marketing efforts are underway and Dova expects to launch a revised strategy in the second quarter of 2019.
The following information was filed by Dova Pharmaceuticals, Inc. (DOVA) on Tuesday, March 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.